Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367821 | 0.84 | EGLN1 (0.73) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL3368461 | 0.84 | NPC1 (0.70) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL2485532 | 0.83 | RAB9A (0.68) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL3365483 | 0.82 | NPC1 (0.67) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL3367654 | 0.81 | RAB9A (0.70) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL2485146 | 0.81 | NPC1 (0.58) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL20705174 | 0.81 | EGLN1 (0.54) | RAB9ANPC1EGLN1KDM4EGAA | |
| SCHEMBL3365520 | 0.81 | NPC1 (0.65) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL3371083 | 0.81 | NPC1 (0.65) | RAB9ANPC1CYP2C9NR4A2EGLN1 | |
| SCHEMBL3366348 | 0.80 | CYP2C9 (0.73) | RAB9ANPC1CYP2C9NR4A2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | claimed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | claimed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | claimed |
| US-8404848-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | NR4A2, NR4A3, NCOR1 | RAB9A 3591/4885NPC1 1018/4885CYP2C9 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.